Oramed Pharmaceuticals

Transforming Injectables into Oral Therapies

Health Tech & Life Sciences
Public on NASDAQ on Apr, 2006<br>Public on TASE on Jul, 2017<br>

Company Overview

Snapshot

Founded in March 2006 by Nadav Kidron and Miriam Kidron, Oramed Pharmaceuticals operates with 11–50 employees. The company has raised $149.13M across 10 funding rounds from 3 investors. Oramed Pharmaceuticals went public on NASDAQ in April 2006.

Business overview

Oramed Pharmaceuticals is a Health Tech & Life Sciences company focused on developing oral delivery solutions for drugs typically administered via injection. Its core technology, the proprietary POD platform, enables the oral administration of protein-based therapies. The company's flagship product is an oral insulin capsule, ORMD-0801, currently in advanced Phase 3 clinical trials for the treatment of type 2 diabetes under the US FDA and European EMA. Oramed Pharmaceuticals serves the pharmaceutical and healthcare industries, aiming to improve the lives of millions of diabetics and potentially other patients requiring protein-based therapies.

Strategic signal

In October 2024, Oramed Pharmaceuticals announced a restructuring of its debt with Scilex Holding Company, indicating an ongoing strategic financial management effort. This development signals the company's focus on optimizing its financial structure and managing its investments, which is crucial for public companies in the clinical-stage pharmaceutical sector.

Company Intelligence Q&A

When did Oramed Pharmaceuticals go public on NASDAQ?
Oramed Pharmaceuticals went public on NASDAQ in April 2006.
What was a significant financial transaction involving Scilex Holding Company in September 2023?
In September 2023, Oramed announced a $101,875,000 short-term senior secured note transaction with Scilex Holding Company.
What was the key development for Oramed's oral insulin program in October 2025?
In October 2025, Oramed released a letter to shareholders highlighting developments in its oral insulin program, including the launch of a new U.S. trial, and noted significant investment appreciation and upcoming growth initiatives.
What was the focus of Oramed's shareholder update in October 2020?
In October 2020, Oramed issued a shareholder update on pivotal Phase 3 oral insulin studies, confirming that protocols had been submitted to the FDA.
What was the status of Oramed's oral insulin trial in November 2020?
In November 2020, Oramed initiated a Phase 3 trial of its oral insulin product.

External links